The perceived effects of marijuana on spinal cord injured males.                      (abst – 1974)


Marihuana as a therapeutic agent for muscle spasm or spasticity.                     (abst – 1980)


Treatment of human spasticity with delta 9-tetrahydrocannabinol.                    (abst – 1981)


Cannabis effect on spasticity in spinal cord injury.                        (abst – 1982)


Effect of Delta-9-THC on EMG Measurements in Human Spasticity                    (abst – 1986)


The effect of delta-9-THC on human spasticity.                    (abst – 1986)


Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. (abst – 1987)


Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.                   (abst – 1989)


Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. (abst + 1st page – 1990)


Nabilone in the treatment of multiple sclerosis.               (abst – 1995)


Treatment of spasticity in spinal cord injury with dronabinol, a tetrahydrocannabinol derivative.  (abst – 1995)


The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.                                              (abst – 1996)


Endocannabinoids control spasticity in a multiple sclerosis model              (full – 2000)  0399fjev1?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=cannabis&andorexactfulltext=and&sear chid=1&FIRSTINDEX=10&sortspec=relevance&resourcetype=HWCIT


Cannabinoids in the treatment of pain and spasticity in multiple sclerosis.             (abst – 2002) tplus


Experiences with THC-treatment in children and adolescents             (abst – 2003)


The treatment of spasticity with D9-tetrahydrocannabinol (D9-THC) in patients with spinal cord injury  (abst – 2003)


Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.         (abst – 2004)


Are oral cannabinoids safe and effective in refractory neuropathic pain?             (abst – 2004)


Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy.Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.            (abst – 2004)


CB1 cannabinoid receptor-mediated modulation of food intake in mice             (full – 2005)


Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.      (abst – 2005)


Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance.       (abst – 2005)


The treatment of spasticity with Delta(9)-tetrahydrocannabinol in persons with spinal cord injury.           (abst – 2006)


Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : A double-blind placebo-controlled cross-over trial.

(abst – 2006) synthetic_cannabinoid_Nabilone_significantly_reduces_spasticity_related_pain_:_A_double_blind_placeb o_controlled_cross_over_trial_


Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis.                                                                      (abst – 2006)


Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors          (full – 2007)


Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis           (full – 2007)


Motor effects of delta 9 THC in cerebellar Lurcher mutant mice.             (abst – 2007)



Cannabinoids in the management of spasticity associated with multiple sclerosis (full – 2008)                         


Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review       (full – 2009)                        


Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain                                                                         (full – 2009)


Marijuana Eases Spasticity in MS Patients                 (news – 2009)


Medical Marijuana and Skeletal Muscular Spasticity                (news – 2009)


Marijuana Chemicals Ease MS Symptoms, Review Confirms                (news – 2009)


Cannabis can reduce spasticity in MS patients               (news – 2009)


Medical Marijuana and Spasticity                (news – 2009)


New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids         (full – 2010)


Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis                                                   (abst – 2010)  xt=cannabis&searchid=1&FIRSTINDEX=0&sortspec=date&resourcetype=HWCIT


Emerging treatment options for spasticity in multiple sclerosis; clinical utility of cannabinoids      (link to PDF – 2011)  ll&recNo=30&uiLanguage=en


A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.     (abst – 2011)


THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.                                                    (abst – 2011)




Cannabinoids in children                 (abst – 2011)


Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.          (full – 2012)               


Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.                                                            (abst – 2012)


Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.     (abst – 2012)                   


Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.    (abst – 2012)







Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity. (abst – 2012)                                


What place for cannabis extract in MS?                  (abst – 2012)


Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids  (abst – 2012)                                   


Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex®) for Spasticity in Multiple Sclerosis.                                                     (abst – 2012)


Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids  (abst – 2012)                               


Smoked Cannabis Reduces Some Symptoms of Multiple Sclerosis                    (news – 2012)  sclerosis.aspx


Cannabis as Painkiller                         (news – 2012)


Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.          (abst – 2013)                      


A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.                                                                (abst – 2013)

Share a link for